{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:29Z","timestamp":1790729069819,"version":"4.1.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Government of Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.euroneuro.2020.01.013","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T07:47:21Z","timestamp":1581320841000},"page":"217-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Possible therapeutic applications of cannabis in the neuropsychopharmacology field"],"prefix":"10.1016","volume":"36","author":[{"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-2434","authenticated-orcid":false,"given":"Ismael","family":"Galve-Roperh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onintza","family":"Sagredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.01.013_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2018.01.003","article-title":"The therapeutic effects of cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report","volume":"49","author":"Abrams","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2985729","article-title":"Report from a survey of parents regarding the use of cannabidiol (medicinal cannabis) in Mexican children with refractory epilepsy","volume":"2017","author":"Aguirre-Vel\u00e1zquez","year":"2017","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0003","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.117","article-title":"Cannabinoids in late-onset Alzheimer's disease","volume":"97","author":"Ahmed","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0004","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tins.2011.03.003","article-title":"Supply and demand for endocannabinoids","volume":"34","author":"Alger","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.14087","article-title":"Efficacy of cannabinoids in paediatric epilepsy","volume":"61","author":"Ali","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pbb.2019.03.006","article-title":"Cannabinoids, interoception, and anxiety","volume":"180","author":"Andrade","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/eat.22173","article-title":"Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial","volume":"47","author":"Andries","year":"2014","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40519-014-0132-5","article-title":"Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial","volume":"20","author":"Andries","year":"2015","journal-title":"Eat. Weight Disord."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0009","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0011","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of Alzheimer\u2019s disease: moving toward the clinic","volume":"5","author":"Aso","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2010.06.007","article-title":"Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype","volume":"21","author":"Aso","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1471-4159.2007.05149.x","article-title":"BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice","volume":"105","author":"Aso","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eplepsyres.2009.01.003","article-title":"Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB1 agonist acea in the pentylenetetrazole-induced seizure in mice","volume":"84","author":"Bahremand","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0016","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0018","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.tpj.6500301","article-title":"Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)","volume":"5","author":"Barrero","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0020","first-page":"19","article-title":"AIDS-associated anorexia","volume":"2","author":"Beal","year":"1995","journal-title":"J. Physicians Assoc. AIDS Care"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0021","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/09540260902782786","article-title":"Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders","volume":"21","author":"Beardsley","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"issue":"10","key":"10.1016\/j.euroneuro.2020.01.013_bib0227","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/acer.14159","article-title":"Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder","volume":"43","author":"Bedse","year":"2019","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0022","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u0394-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0023","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.phrs.2016.07.021","article-title":"Type-2 cannabinoid receptors in neurodegeneration","volume":"111","author":"Bisogno","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0024","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","article-title":"Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress","volume":"62","author":"Bortolato","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ajad.12963","article-title":"Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential","volume":"29","author":"Botsford","year":"2020","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09540260902782760","article-title":"Basic neuroanatomy and neuropharmacology of cannabinoids","volume":"21","author":"Breivogel","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0028","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0000000000000129","article-title":"Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis","volume":"34","author":"Brunt","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0029","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.addbeh.2012.10.010","article-title":"Psychometric properties of a valuations scale for the marijuana effect expectancies questionnaire","volume":"38","author":"Buckner","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nm.3127","article-title":"Targeting the endocannabinoid system in the treatment of fragile x syndrome","volume":"19","author":"Busquets-Garcia","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0031","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1098\/rstb.2011.0386","article-title":"Functional diversity on synaptic plasticity mediated by endocannabinoids","volume":"367","author":"Cachope","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0032","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006103.pub5","article-title":"Cannabinoid type 1 receptor antagonists for smoking cessation","volume":"3","author":"Cahill","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0033","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.01.013_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsx184","article-title":"Pharmacotherapy of apnea by cannabimimetic enhancement, the pace clinical trial: effects of dronabinol in obstructive sleep apnea","volume":"41","author":"Carley","year":"2018","journal-title":"Sleep"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","article-title":"Endocannabinoid signaling and synaptic function","volume":"76","author":"Castillo","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0036","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0037","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/1060028018822124","article-title":"Cannabidiol: a new hope for patients with dravet or lennox-gastaut syndromes","volume":"53","author":"Chen","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0038","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0039","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/adb.12652","article-title":"Alteration to hippocampal volume and shape confined to cannabis dependence: a multi-site study","volume":"24","author":"Chye","year":"2019","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12035-007-0017-y","article-title":"The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence","volume":"36","author":"Colombo","year":"2007","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0041","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/can.2018.0030","article-title":"Regulatory status of cannabidiol in the united states: a perspective","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0042","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/npp.2015.53","article-title":"\u03949-THC disrupts gamma (\u03b3)-band neural oscillations in humans","volume":"40","author":"Cortes-Briones","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0043","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/hup.1048","article-title":"Cannabis and anxiety: a critical review of the evidence","volume":"24","author":"Crippa","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0044","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/febs.12125","article-title":"Epigenetic mechanisms and endocannabinoid signalling","volume":"280","author":"D'Addario","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2017.01.022","article-title":"A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia","volume":"188","author":"D\u2019Addario","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0046","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2018.03.013","article-title":"The psychiatric consequences of cannabinoids","volume":"40","author":"De Aquino","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0047","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0048","doi-asserted-by":"crossref","first-page":"13693","DOI":"10.1073\/pnas.1514962112","article-title":"Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons","volume":"112","author":"de Salas-Quiroga","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0049","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow","volume":"29","author":"De Souza Crippa","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nm1001-1151","article-title":"A cannabinoid mechanism in relapse to cocaine seeking","volume":"7","author":"De Vries","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0051","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0052","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0053","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0054","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0055","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nbd.2014.10.018","article-title":"Post-status epilepticus treatment with the cannabinoid agonist win 55,212-2 prevents chronic epileptic hippocampal damage in rats","volume":"73","author":"Di Maio","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0056","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","article-title":"The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0057","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuroscience.2011.08.049","article-title":"Cannabinoid type 1 receptors located on single-minded 1-expressing neurons control emotional behaviors","volume":"204","author":"Dubreucq","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0058","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0059","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.phrs.2009.12.013","article-title":"A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy","volume":"61","author":"Eisenstein","year":"2010","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from cannabis sativa l","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0061","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2215-0366(17)30075-5","article-title":"Can we make cannabis safer?","volume":"4","author":"Englund","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0062","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1046\/j.1460-9568.2003.02607.x","article-title":"Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats","volume":"17","author":"Fattore","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0063","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/j.1755-5949.2010.00144.x","article-title":"Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Fern\u00e1ndez-Ruiz","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0064","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","article-title":"Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?","volume":"75","author":"Fern\u00e1ndez-Ruiz","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0065","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.neuron.2013.02.036","article-title":"Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling","volume":"78","author":"F\u00f6ldy","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0066","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","article-title":"Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies","volume":"13","author":"Foll","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0067","doi-asserted-by":"crossref","first-page":"l1141","DOI":"10.1136\/bmj.l1141","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0068","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","article-title":"Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders","volume":"18","author":"Friedman","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0069","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1461145709990617","article-title":"Modulation of effective connectivity during emotional processing by \u03949-tetrahydrocannabinol and cannabidiol","volume":"13","author":"Fusar-Poli","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archgenpsychiatry.2008.519","article-title":"Distinct effects of \u03949-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing","volume":"66","author":"Fusar-Poli","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0071","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40263-019-00664-w","article-title":"Potential of cannabinoid receptor ligands as treatment for substance use disorders","volume":"33","author":"Galaj","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0072","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fpsyt.2015.00041","article-title":"Role of the endogenous cannabinoid system in nicotine addiction: novel insights","volume":"6","author":"Gamaleddin","year":"2015","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0073","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ajad.12291","article-title":"Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: a focused review","volume":"24","author":"Garcia","year":"2015","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0074","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","article-title":"The effects of cannabinoid administration on sleep: a systematic review of human studies","volume":"18","author":"Gates","year":"2014","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biopsych.2011.05.010","article-title":"Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa","volume":"70","author":"G\u00e9rard","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0076","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajhg.2012.12.016","article-title":"Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder","volume":"92","author":"Girirajan","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0077","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0078","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0079","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors","volume":"213","author":"Gomes","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.pbb.2005.01.028","article-title":"Cannabinoid tolerance and dependence: a review of studies in laboratory animals","volume":"8","author":"Gonz\u00e1lez","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0081","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00004714-198306000-00004","article-title":"A double-blind trial of \u22069-tetrahydrocannabinol in primary anorexia nervosa","volume":"3","author":"Gross","year":"1983","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0082","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00213-005-2242-2","article-title":"Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood","volume":"181","author":"Haney","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0083","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2011.12.035","article-title":"Neuronal populations mediating the effects of endocannabinoids on stress and emotionality","volume":"204","author":"H\u00e4ring","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0084","article-title":"Cannabis use and psychosis: a review of reviews","author":"Hasan","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0085","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile x syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0087","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euroneuro.2005.03.003","article-title":"Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test","volume":"15","author":"Hill","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0088","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0089","article-title":"Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review","volume":"15","author":"Hillen","year":"2019","journal-title":"Ther. Adv. Drug Saf"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0090","first-page":"1","article-title":"The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): a systematic review","author":"Hindocha","year":"2019","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0091","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","author":"Hoch","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0092","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.mp.4001376","article-title":"Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims","volume":"9","author":"Hungund","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2020.01.013_bib0093","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0094","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and lennox-gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0095","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awg143","article-title":"Cannabis and the brain","volume":"126","author":"Iversen","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0096","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.euroneuro.2018.12.014","article-title":"A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis","volume":"29","author":"Jacobson","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0097","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2018.2728","article-title":"Association of autism spectrum disorder with prenatal exposure to medication affecting neurotransmitter systems","volume":"75","author":"Janecka","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0098","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/14728214.2012.660916","article-title":"Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse\/drug addiction with CB1R neutral antagonists","volume":"17","author":"Janero","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0099","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0101","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/ncomms2045","article-title":"Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile x syndrome","volume":"3","author":"Jung","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00019.2008","article-title":"Endocannabinoid-mediated control of synaptic transmission","volume":"89","author":"Kano","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0103","doi-asserted-by":"crossref","unstructured":"Kaplan, J.S., Stella, N., Catterall, W.A., Westenbroek, R.E., 2017. Cannabidiol Attenuates Seizures and Social Deficits in a Mouse Model of Dravet Syndrome. 114, 11229\u201311234.","DOI":"10.1073\/pnas.1711351114"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0104","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0024-3205(74)90009-5","article-title":"Anticonvulsant properties of \u03949-tetrahydrocannabinol and other cannabinoids","volume":"15","author":"Karler","year":"1974","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0106","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of \u03949-tetrahydrocannabinol in man","volume":"2","author":"Karniol","year":"1974","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0107","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-neuro-062111-150420","article-title":"Multiple functions of endocannabinoid signaling in the brain","volume":"35","author":"Katona","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0108","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fneur.2018.00731","article-title":"Cannabidiol for treatment of childhood epilepsy \u2013 a cross-sectional survey","volume":"9","author":"Klotz","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0111","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.drugalcdep.2015.05.014","article-title":"Is cannabis use associated with less opioid use among people who inject drugs?","volume":"153","author":"Kral","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0112","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1037\/pha0000285","article-title":"The use of cannabinoids for sleep: a critical review on clinical trials","volume":"27","author":"Kuhathasan","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0113","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0114","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatmentresistant lennox-gastaut syndrome or dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0115","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","article-title":"Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence","volume":"312","author":"Le Foll","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0116","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaac.2016.12.014","article-title":"Evidence for the risks and consequences of adolescent cannabis exposure","volume":"56","author":"Levine","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0117","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0118","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0119","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1369-1600.2008.00105.x","article-title":"The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction","volume":"13","author":"L\u00f3pez-Moreno","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0120","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1523\/JNEUROSCI.4465-07.2008","article-title":"Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus","volume":"28","author":"Lud\u00e1nyi","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0121","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pbb.2011.01.002","article-title":"Synthetic cannabinoid win 55,212-2 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice","volume":"98","author":"Luszczki","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0122","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0123","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/187152710790966623","article-title":"Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data","volume":"9","author":"Maccioni","year":"2010","journal-title":"CNS Neurol. Disord. \u2013 Drug Targets"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0124","first-page":"299","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuroscience.2011.02.035","article-title":"Neurochemical basis of cannabis addiction","volume":"181","author":"Maldonado","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0126","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0127","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/138161208785740135","article-title":"Expression and function of the endocannabinoid system in glial cells","volume":"14","author":"Massi","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcp.2018.08.012","article-title":"Selective up-regulation of cannabinoid CB1 receptor coupling to go-proteins in suicide victims with mood disorders","volume":"157","author":"Mato","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0129","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/acn3.621","article-title":"A prospective open-label trial of a CBD\/THC cannabis oil in dravet syndrome","volume":"5","author":"McCoy","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: priming a target for new therapies","volume":"38","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0132","series-title":"Cannabinoid Modulation of Emotion, Memory, and Motivation","first-page":"97","article-title":"Role of the endocannabinoid system in depression: from preclinical to clinical evidence","author":"Micale","year":"2015"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0133","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(07)61705-X","article-title":"Depression and anxiety with rimonabant","volume":"370","author":"Mitchell","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0134","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.phrs.2010.01.002","article-title":"Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression","volume":"61","author":"Monteleone","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0135","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.npp.1300695","article-title":"Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa","volume":"30","author":"Monteleone","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0136","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0226","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/7854_2009_16","article-title":"Cannabinoids and anxiety","volume":"2","author":"Moreira","year":"2010","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0137","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0138","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.physbeh.2009.04.023","article-title":"Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission","volume":"98","author":"Morrish","year":"2009","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0139","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous \u22069- tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"M\u00fcller-Vahl","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0141","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.pnpbp.2008.04.008","article-title":"The role of the CB1 receptor in the regulation of sleep","volume":"32","author":"Murillo-Rodr\u00edguez","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0142","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s13311-011-0100-y","article-title":"Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase \u2013 dual targets of the endocannabinoid system to protect against seizure pathology","volume":"9","author":"Naidoo","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0143","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-006-0689-4","article-title":"Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality","volume":"192","author":"Naidu","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0144","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.neuron.2008.01.029","article-title":"Endocannabinoids mediate neuron-astrocyte communication","volume":"57","author":"Navarrete","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuron.2010.08.043","article-title":"Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes","volume":"68","author":"Navarrete","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0146","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nbd.2019.01.014","article-title":"Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for down syndrome","volume":"125","author":"Navarro-Romero","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0147","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pnpbp.2019.03.017","article-title":"Cannabinoid interventions for PTSD: where to next?","volume":"93","author":"Ney","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0148","doi-asserted-by":"crossref","first-page":"332","DOI":"10.7326\/M17-0477","article-title":"Benefits and harms of plant-based cannabis for posttraumatic stress disorder a systematic review","volume":"167","author":"O'Neil","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0149","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fpsyt.2013.00109","article-title":"Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction","volume":"4","author":"Oli\u00e8re","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1432.036","article-title":"Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression","volume":"1139","author":"Onaivi","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0151","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/medicina55090525","article-title":"Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review","volume":"55","author":"Orsolini","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0152","first-page":"443","article-title":"Endocannabinoid system in cancer cachexia","volume":"10","author":"Osei-Hyiaman","year":"2007","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0153","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","article-title":"GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia","volume":"21","author":"Pasman","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0154","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.alcohol.2012.01.002","article-title":"A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research","volume":"4","author":"Pava","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainresrev.2009.10.005","article-title":"Glia modulates synaptic transmission","volume":"6","author":"Perea","year":"2010","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0156","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.tins.2009.05.001","article-title":"Tripartite synapses: astrocytes process and control synaptic information","volume":"32","author":"Perea","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0157","first-page":"1","article-title":"Ventral hippocampal overexpression of cannabinoid receptor interacting protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat","volume":"1","author":"Perez","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0158","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International union of basic and clinical pharmacology. LXXIX. cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0159","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0160","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.lfs.2018.09.058","article-title":"Cannabinoids in depressive disorders","volume":"213","author":"Poleszak","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0161","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0162","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav."},{"issue":"9","key":"10.1016\/j.euroneuro.2020.01.013_bib0163","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0164","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia","volume":"79","author":"Ranganathan","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/npp.2013.164","article-title":"Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice","volume":"38","author":"Raver","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0166","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0167","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","article-title":"Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway","volume":"36","author":"Renard","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0168","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2008.00046.x","article-title":"5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats","volume":"156","author":"Resstel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0169","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-328X(02)00167-5","article-title":"Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study","volume":"100","author":"Romero","year":"2002","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0170","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1528-1167.2009.02334.x","article-title":"Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy","volume":"51","author":"Romigi","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0171","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1358\/dnp.2008.21.3.1203411","article-title":"The role of the endogenous cannabinoid system in drug addiction","volume":"21","author":"Rubino","year":"2008","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0172","doi-asserted-by":"crossref","first-page":"e00220","DOI":"10.1002\/prp2.220","article-title":"Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with dravet syndrome","volume":"4","author":"Rubio","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0173","article-title":"Agitation, oxidative stress, and cytokines in alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation","author":"Ruthirakuhan","year":"2019","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0174","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","article-title":"Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels","volume":"86","author":"Sales","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.biopsych.2016.07.007","article-title":"CB1 cannabinoid receptors mediate cognitive deficits and structural plasticity changes during nicotine withdrawal","volume":"81","author":"Saravia","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107402","article-title":"Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders","volume":"204","author":"Sartori","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0177","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuroscience.2013.04.034","article-title":"Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal","volume":"248","author":"Scavone","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0178","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2174\/187152708786927859","article-title":"The endocannabinoid system: a new molecular target for the treatment of tobacco addiction","volume":"7","author":"Scherma","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0179","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00213-015-4196-3","article-title":"Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives","volume":"233","author":"Scherma","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0181","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pharmthera.2011.06.005","article-title":"Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors","volume":"132","author":"Serrano","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0182","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1038\/tp.2016.182","article-title":"Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid","volume":"6","author":"Servadio","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0183","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09540260902782802","article-title":"Cannabinoids and psychosis","volume":"21","author":"Sewell","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0184","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","article-title":"Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice","volume":"14","author":"Shearman","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0185","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2015.12.011","article-title":"It\u2019s all in the rhythm: the role of cannabinoids in neural oscillations and psychosis","volume":"79","author":"Skosnik","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0186","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2017.05.031","article-title":"The endocannabinoid system as a target for addiction treatment: trials and tribulations","volume":"124","author":"Sloan","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0187","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrn3937","article-title":"Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy","volume":"16","author":"Soltesz","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0188","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuropharm.2018.11.035","article-title":"Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the mam model of schizophrenia","volume":"146","author":"Stark","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0189","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/da.22596","article-title":"Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review","volume":"3","author":"Steenkamp","year":"2017","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0190","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.psyneuen.2008.06.004","article-title":"Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0191","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","article-title":"Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas","volume":"5","author":"Stella","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0192","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"Strasser","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0193","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1054\/plef.2001.0356","article-title":"Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance","volume":"66","author":"Sugiura","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0194","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2016.08.004","article-title":"The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats","volume":"334","author":"Suleymanova","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.yebeh.2017.02.005","article-title":"An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use","volume":"70","author":"Suraev","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0196","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0197","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0198","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0199","first-page":"231","article-title":"Anticonvulsant properties of cannabidiol","volume":"8","author":"Turkanis","year":"1974","journal-title":"Res.Commun.Chem.Path.Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2011.04.031","article-title":"Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice","volume":"223","author":"Umathe","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0202","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial","volume":"23","author":"Van Den Elsen","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0203","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"Van Den Elsen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0204","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0269881116665357","article-title":"Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial","volume":"31","author":"Van Den Elsen","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2337\/dc08-s258","article-title":"Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program","volume":"31","author":"Van Gaal","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0206","first-page":"83","article-title":"New approaches for the management of patients with multiple cardiometabolic risk factors","volume":"29","author":"Van Gaal","year":"2006","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0207","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.biopsych.2004.11.033","article-title":"Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims","volume":"57","author":"Vinod","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0208","doi-asserted-by":"crossref","first-page":"e36743","DOI":"10.1371\/journal.pone.0036743","article-title":"Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in wistar kyoto rats","volume":"7","author":"Vinod","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0209","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0211","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.nbd.2015.03.016","article-title":"Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice","volume":"77","author":"von R\u00fcden","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0212","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0213","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0214","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0215","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0216","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/can.2018.0022","article-title":"Emerging evidence for cannabis\u2019 role in opioid use disorder","volume":"3","author":"Wiese","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0217","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40429-014-0018-7","article-title":"Impact of cannabis use on the development of psychotic disorders","volume":"1","author":"Wilkinson","year":"2014","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0218","first-page":"195","article-title":"Anorexia of aging in long term care: is dronabinol an effective appetite stimulant? A pilot study","volume":"11","author":"Wilson","year":"2007","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0219","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1369-1600.2008.00109.x","article-title":"The role of CB1 receptors in psychostimulant addiction","volume":"13","author":"Wiskerke","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpainsymman.2004.07.011","article-title":"Cannabis use in HIV for pain and other medical symptoms","volume":"29","author":"Woolridge","year":"2005","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0221","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB2 receptors modulate cocaine's actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0222","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0269881119844184","article-title":"Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male mecp2 mutant mice","volume":"33","author":"Zamberletti","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0223","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT 1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0224","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.01.013_bib0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroscience.2010.07.004","article-title":"CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies","volume":"170","author":"Zurolo","year":"2010","journal-title":"Neuroscience"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:58:20Z","timestamp":1760378300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20300365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":227,"alternative-id":["S0924977X20300365"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.013","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible therapeutic applications of cannabis in the neuropsychopharmacology field","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}